Company page

Transgene Sa

Transgene SA is a public company listed on the French market under the ticker TNG, with a market capitalization of approximately €232.75 million. The company focuses on developing innovative immunotherapies for the treatment of cancer and infectious diseases. Transgene is committed to advancing its proprietary technologies to improve patient outcomes.